We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
326
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.19M | 0.07% |
237,000
+19,000
| +9% | +$386K |
|
327
Zoetis
ZTS
$31.6B
| $4.15M | 0.07% |
48,743
-2,069
| -4% | -$175K |
|
328
Norfolk Southern
NSC
$78.8B
| $4.13M | 0.07% |
27,356
+1,993
| +8% | +$291K |
|
329
CytomX Therapeutics
CTMX
$705M
| $4.12M | 0.07% |
180,127
+139,127
| +339% | +$3.55M |
|
|
GBT
330
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.11M | 0.07% |
91,000
+14,000
| +18% | +$637K |
|
331
Analog Devices
ADI
$181B
| $4.11M | 0.07% |
42,805
-28,720
| -40% | -$2.71M |
|
332
Intercontinental Exchange
ICE
$82.4B
| $4.1M | 0.06% |
55,682
-1,850
| -3% | -$135K |
|
|
MDCO
333
DELISTED
Medicines Co
MDCO
| $4.06M | 0.06% |
110,500
+22,500
| +26% | +$731K |
|
334
BorgWarner
BWA
$13.2B
| $4.05M | 0.06% |
106,627
-144,574
| -58% | -$6.37M |
|
335
HP
HPQ
$23.5B
| $4.04M | 0.06% |
177,882
+23,576
| +15% | +$526K |
|
336
Exelon
EXC
$48.6B
| $3.98M | 0.06% |
130,903
+13,523
| +12% | +$387K |
|
337
Zillow
Z
$7.04B
| $3.96M | 0.06% |
+67,058
| New | +$3.72M |
|
338
Simon Property Group
SPG
$74.5B
| $3.95M | 0.06% |
23,222
-5,577
| -19% | -$887K |
|
|
PXD
339
DELISTED
Pioneer Natural Resource Co.
PXD
| $3.94M | 0.06% |
20,835
+3,163
| +18% | +$606K |
|
340
Huntington Bancshares
HBAN
$35.1B
| $3.92M | 0.06% |
265,346
+93,049
| +54% | +$1.4M |
|
|
WP
341
DELISTED
Worldpay, Inc.
WP
| $3.91M | 0.06% |
47,820
-56,826
| -54% | -$4.64M |
|
342
Duke Energy
DUK
$102B
| $3.88M | 0.06% |
49,004
-7,258
| -13% | -$558K |
|
343
Southern Company
SO
$110B
| $3.78M | 0.06% |
81,707
+3,812
| +5% | +$171K |
|
344
Lam Research
LRCX
$382B
| $3.74M | 0.06% |
216,120
+4,160
| +2% | +$80.1K |
|
345
Watsco Inc
WSO
$14.9B
| $3.69M | 0.06% |
+20,704
| New | +$3.77M |
|
346
International Paper
IP
$22.3B
| $3.67M | 0.06% |
74,348
-50,375
| -40% | -$2.57M |
|
347
VeriSign
VRSN
$25.3B
| $3.67M | 0.06% |
26,669
+16,542
| +163% | +$2.12M |
|
|
348
Corning
GLW
$126B
| $3.65M | 0.06% |
132,530
-481,606
| -78% | -$13.3M |
|
|
ULTI
349
DELISTED
Ultimate Software Group Inc
ULTI
| $3.64M | 0.06% |
+14,145
| New | +$3.63M |
|
350
Conagra Brands
CAG
$7.07B
| $3.63M | 0.06% |
101,589
+17,236
| +20% | +$642K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.